FR-171113

FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM.[1][2][3][4].

Product Specifications

CAS Number

[173904-50-2]

UNSPSC

12352005

Hazard Statement

H410

Target

Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/fr-171113.html

Solubility

10 mM in DMSO

Smiles

O=C(OC)/C=C(S/C(N1C2=CC=C(Cl)C=C2)=N\C(C3=CC=C(Cl)C=C3Cl)=O)/C1=O

Molecular Formula

C19H11Cl3N2O4S

Molecular Weight

469.73

Precautions

P273-P391-P501

References & Citations

[1]Y Kato, et al. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384 (2-3) :197-202.|[2]Yuji Ishibashi, et al. Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc Diabetol. 2014 Mar 13;13:60.|[3]Misa Tanaka, et al. Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation. Kidney Int. 2005 Jun;67 (6) :2123-33.|[4]Yasuko Kato, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003 Jul 25;473 (2-3) :163-9.